Ligand Pharmaceuticals Inc ( (LGND) ) has released its Q1 earnings. Here is a breakdown of the information Ligand Pharmaceuticals Inc presented to its investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Ligand Pharmaceuticals Inc. is a biopharmaceutical company that supports the clinical development of high-value medicines through financing and technology licensing, operating primarily in the biotech and pharmaceutical sectors. The company is known for its royalty aggregation model, which provides a diversified portfolio of revenue streams.
In its first quarter of 2025, Ligand Pharmaceuticals reported a significant increase in revenue, driven by a 44% growth in royalty revenue. The company also strengthened its commercial portfolio through strategic transactions with Channel Therapeutics and Castle Creek Biosciences, and reiterated its financial guidance for the year.
Key financial highlights include a 46% increase in total revenues to $45.3 million, primarily due to higher royalty revenue and Captisol sales. However, the company reported a GAAP net loss of $42.5 million, attributed to increased research and development expenses and a one-time charge related to a royalty financing agreement. Ligand’s core adjusted net income rose to $26.6 million, reflecting the revenue growth.
Looking ahead, Ligand Pharmaceuticals maintains its revenue forecast for 2025, expecting total revenues between $180 million and $200 million, with adjusted earnings per diluted share ranging from $6.00 to $6.25. The company continues to focus on expanding its portfolio and leveraging strategic partnerships to drive future growth.